Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 abemaciclib study in patients with brain metastases from HR-positive breast cancer, non-small cell lung cancer, or melanoma
MOH_2017-05-09_000214Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of abemaciclib in breast cancer, non-small cell lung cancer (NSCLC) and melanoma (6 arms), sponsored by Eli Lilly and Company. Started Oct 2015; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on MOH_2017-05-09_000214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-09_000214.